Companies with positive PBAC recommendations from November are already dealing with the indirect consequences of next April and it is just one of the challenges facing pharmaceutical, medical device and diagnostic companies as we look forward to 2023.
Next year will be even tougher unless the downward trajectory can be halted
December 8, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Is there any example of another review or inquiry taking this long?
April 10, 2026 - - Latest News -
Rewriting the rules of PBS negotiations to deliver a patient-first reset
April 10, 2026 - - Latest News -
A decade of readiness as AVITA medical expands burn response capability
April 9, 2026 - - Australian Biotech -
Moderna names Carolyn Tucek-Szabo to lead Australia and New Zealand operations
April 9, 2026 - - Latest News -
New Zealand's Pharmac announces a shift in treatment for blood cancer
April 9, 2026 - - Latest News -
It is imperative to very carefully read what the minister said, and then read it again
April 9, 2026 - - Latest News -
Stuart Dignam joins MTPConnect board as it embarks on its second decade
April 8, 2026 - - Latest News
